Axsome Soars After Depression Trial Success

$1bn+ Peak Revenues Forecast Once Approved

 
• By Andrew McConaghie
  
Brain_Stress
New depression treatments remain rare, though J&J's Spravato gained approval earlier this year
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D